keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/29147854/nolan-a-randomized-phase-2-study-to-estimate-the-effect-of-prophylactic-naproxen-or-loratadine-vs-no-prophylactic-treatment-on-bone-pain-in-patients-with-early-stage-breast-cancer-receiving-chemotherapy-and-pegfilgrastim
#1
Jeffrey J Kirshner, Maxwell C McDonald, Flavio Kruter, Andrew S Guinigundo, Linda Vanni, Cathy L Maxwell, Maureen Reiner, Terry E Upchurch, Jacob Garcia, Phuong Khanh Morrow
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluated the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on pegfilgrastim-associated bone pain. METHODS: In this open-label study (NCT01712009), women ≥ 18 years of age with newly diagnosed stage I-III breast cancer and an ECOG performance status ≤ 2 who were planning ≥ 4 cycles of adjuvant or neoadjuvant chemotherapy with pegfilgrastim support starting in cycle 1 were randomized 1:1:1 to receive naproxen, loratadine, or no treatment to prevent pegfilgrastim-associated bone pain...
November 16, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29146938/computational-investigation-of-homologous-recombination-dna-repair-deficiency-in-sporadic-breast-cancer
#2
Yue Wang, Matthew H Ung, Sharon Cantor, Chao Cheng
BRCAness has important implications in the management and treatment of patients with breast and ovarian cancer. In this study, we propose a computational framework to measure the BRCAness of breast and ovarian tumor samples based on their gene expression profiles. We define a characteristic profile for BRCAness by comparing gene expression differences between BRCA1/2 mutant familial tumors and sporadic breast cancer tumors while adjusting for relevant clinical factors. With this BRCAness profile, our framework calculates sample-specific BRCA scores, which indicates homologous recombination (HR)-mediated DNA repair pathway activity of samples...
November 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29146401/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast-cancer-extenet-5-year-analysis-of-a-randomised-double-blind-placebo-controlled-phase-3-trial
#3
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Stephen K L Chia, Janine Mansi, Carlos H Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Erhan Gokmen, Anna Bashford, Manuel Ruiz Borrego, Sung-Bae Kim, Erik Hugger Jakobsen, Audrone Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B Heijns, Anne C Armstrong, John S Link, Anil Abraham Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan
BACKGROUND: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings. METHODS: In this ongoing randomised, double-blind, placebo-controlled, phase 3 trial, eligible women aged 18 years or older (≥20 years in Japan) with stage 1-3c (modified to stage 2-3c in February, 2010) operable breast cancer, who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab with no evidence of disease recurrence or metastatic disease at study entry...
November 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29146052/phenotypic-alterations-in-breast-cancer-associated-with-neoadjuvant-chemotherapy-a-comparison-with-baseline-rates-of-change
#4
Nosaibah Hariri, Andres A Roma, Farnaz Hasteh, Vighnesh Walavalkar, Oluwole Fadare
Several studies have documented phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy [NACT], but many of these studies are limited by the fact that they did not account for the baseline rate of expected phenotypic change between biopsies and resections in the absence of NACT. Herein, we assess whether the NACT-associated rate of phenotypic change is significantly different than would be expected in a control population of patients that did not receive NACT. From a pathologic database, we documented the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2/neu) phenotypes of consecutive invasive breast carcinomas (n=826), as well as the subset in which at least one of these tests was assessed in both the biopsy and resection (n=340)...
December 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29145297/therapeutic-effect-of-neoadjuvant-chemotherapy-combined-with-curettage-to-treat-distal-femoral-osteosarcoma-a-case-report
#5
Qi Lai, Conglin Ye, Tian Gao, Jun Xiao, An Xie, Xuqiang Liu, Xiaolong Yu, Jun Liu, Min Dai, Hucheng Liu, Bin Zhang
RATIONALE: Osteosarcoma is the most common malignant bone tumor in children and adolescents. Metastasis occurs early, the mortality rate is high, and the tumor results in a tremendous physical, mental, and economic burden on patients. Therefore, the treatment of osteosarcoma has been important for orthopedic surgeons. However, treatment has always been a difficult problem globally. PATIENT CONCERN: We present the case of a 22-year-old girl with increasing local pain in the distal left thigh...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29143898/the-multidisciplinary-approach-to-localized-pancreatic-adenocarcinoma
#6
REVIEW
Hiral D Parekh, Jason Starr, Thomas J George
Pancreatic adenocarcinoma 2030 (PCa) is predicted to be the second leading cause of cancer death in USA by 2030. To date, attempts at early detection have been unsuccessful. Therapies for resectable PCa include surgery followed by adjuvant chemotherapy with or without radiotherapy. Unfortunately, most patients with PCa present with advanced disease and thus only 20% of patients are potentially resectable upon presentation. Improved surgical techniques along with adjuvant combination chemotherapy have improved outcomes for patients with resectable disease...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29142865/osteosarcoma-of-the-jaws-in-koreans-analysis-of-26-cases
#7
Hye-In Jeong, Mi Jee Lee, Woong Nam, In-Ho Cha, Hyung Jun Kim
Objectives: In order to assess clinical behavior, response to treatment, and factors influencing prognosis of Korean patients with osteosarcoma of the jaws (OSJ). Materials and Methods: A retrospective study of clinical, and pathological records of 26 patients with OSJ treated at the Department of Oral and Maxillofacial Surgery in Yonsei University Dental Hospital from 1990 to March 2017. Results: Of 26 patients, there were 9 men (34.6%) and 17 women (65...
October 2017: Journal of the Korean Association of Oral and Maxillofacial Surgeons
https://www.readbyqxmd.com/read/29142805/role-of-adjuvant-treatment-in-sinonasal-mucosal-melanoma
#8
Moran Amit, Samantha Tam, Ahmed S Abdelmeguid, Michael E Kupferman, Shirley Y Su, Shaan M Raza, Franco DeMonte, Ehab Y Hanna
Purpose  Sinonasal mucosal melanoma (SNMM) is a locally aggressive tumor. This study aimed to define the role of adjuvant treatment and its association with survival outcomes of SNMM. Methods  This retrospective study investigated 152 patients with SNMM treated between 1991 and 2016 in MD Anderson Cancer Center. Patients were divided into the following treatment groups: surgery alone, surgery with postoperative radiotherapy (PORT), surgery with postoperative chemoradiation (POCRT), and induction chemotherapy followed by surgery and PORT...
December 2017: Journal of Neurological Surgery. Part B, Skull Base
https://www.readbyqxmd.com/read/29142750/evaluation-of-epidermal-growth-factor-receptor-serum-levels-and-their-association-with-clinicopathological-characteristics-in-patients-with-colorectal-cancer
#9
Mehmet Karabulut, Cigdem Usul Afsar, Halil Alıs, Ebru Oran, Senem Karabulut, Cevher Akarsu, Nuri Alper Sahbaz, Alpen Yahya Gümüsoglu, Elif Bilgin, Nuri Faruk Aykan
Colorectal cancer (CRC) is a major public health concern and one of the leading causes of cancer-related mortality worldwide. The aim of the present study was to determine the serum epidermal growth factor receptor (sEGFR) levels in healthy volunteers and patients with CRC, to determine the association between tumor marker levels and clinicopathological findings, and investigate its prognostic value. A total of 140 patients with CRC were enrolled in the present study. Pre-treatment sEGFR levels were determined using ELISA...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29142367/case-of-carcinoma-breast-with-unusually-large-tumor-thrombus-in-superior-vena-cava-detected-on-18-f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-scan
#10
Arun Sasikumar, Anto Baby, Mathews Jose, Retcy Mary Paul
A 60-year-old female with triple negative breast cancer, postsurgery, neoadjuvant chemotherapy and radiotherapy, on follow-up had facial puffiness and giddiness. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) done for suspected recurrence evaluation revealed a large tumor thrombus (TT) in superior vena cava (SVC) with radiological evidence of SVC obstruction. (18)F-FDG PET/CT also showed evidence of FDG avid brain metastases, lymph nodal metastases, and metastatic soft tissue deposits...
October 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/29138989/sexual-function-and-sex-hormones-in-breast-cancer-patients
#11
Antonio Gambardella, Daniela Esposito, Giacomo Accardo, Marianna Taddeo, Antonietta Letizia, Rossella Tagliafierro, Katherine Esposito, Daniela Pasquali
PURPOSE: Breast cancer patients (BCP) are at risk of female sexual dysfunction (FSD). Our aim was to clarify the effects of treatment strategies, and steroid hormones levels on FSD. METHODS: We enrolled 136 BCP (46.9 ± 0.8 years), and 122 completed questionnaires. BCP were divided into four groups: 22 women with advanced breast cancer on neoadjuvant therapy (NAT), 48 on adjuvant therapy (AT), 30 taking hormonal therapy (HT) and 22 with metastatic cancer on first line chemotherapy (FLT)...
November 14, 2017: Endocrine
https://www.readbyqxmd.com/read/29138861/immunogenic-tumor-cell-death-induced-by-chemotherapy-in-patients-with-breast-cancer-and-esophageal-squamous-cell-carcinoma
#12
Keita Aoto, Kousaku Mimura, Hirokazu Okayama, Motonobu Saito, Shun Chida, Masaru Noda, Takahiro Nakajima, Katsuharu Saito, Noriko Abe, Shinji Ohki, Tohru Ohtake, Seiichi Takenoshita, Koji Kono
It has been reported that chemo-radiotherapy can induce immunogenic tumor cell death (ICD), which triggers T-cell immunity mainly mediated by high-mobility group box 1 protein (HMGB1) and calreticulin. However, there is still limited information to support this theory relating to chemotherapy alone. In the present study, the expression of HMGB1 and calreticulin was evaluated by immunohistochemistry in pre-treatment biopsy specimens and surgically resected specimens, which were obtained from patients with breast cancer (n=52) and esophageal squamous cell carcinoma (ESCC) (n=8) who had been treated with neoadjuvant chemotherapy (NAC)...
November 14, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29138631/sarc006-phase-ii-trial-of-chemotherapy-in-sporadic-and-neurofibromatosis-type-1-associated-chemotherapy-naive-malignant-peripheral-nerve-sheath-tumors
#13
Christine S Higham, Seth M Steinberg, Eva Dombi, Arie Perry, Lee J Helman, Scott M Schuetze, Joseph A Ludwig, Arthur Staddon, Mohammed M Milhem, Daniel Rushing, Robin L Jones, Michael Livingston, Stewart Goldman, Christopher Moertel, Lars Wagner, David Janhofer, Christina M Annunziata, Denise Reinke, Lauren Long, David Viskochil, Larry Baker, Brigitte C Widemann
Background: Worse chemotherapy response for neurofibromatosis type 1- (NF1-) associated compared to sporadic malignant peripheral nerve sheath tumors (MPNST) has been reported. Methods: We evaluated the objective response (OR) rate of patients with AJCC Stage III/IV chemotherapy-naive NF1 MPNST versus sporadic MPNST after 4 cycles of neoadjuvant chemotherapy, 2 cycles of ifosfamide/doxorubicin, and 2 cycles of ifosfamide/etoposide. A Simon optimal two-stage design was used (target response rate 40%)...
2017: Sarcoma
https://www.readbyqxmd.com/read/29138382/-a-case-of-retroperitoneal-abscess-due-to-acute-appendicitis-during-neo-adjuvant-chemotherapy-for-breast-cancer
#14
Takaaki Oba, Kazuma Maeno, Kenichi Ito, Satoshi Ishizone, Takaomi Hanaoka
When acute appendicitis occurs in patients treated with chemotherapy, neutropenia and abdominal complaints caused by chemotherapy can contribute to the diagnostic difficulty, masking the increase in white blood cell(WBC)counts and physical findings of acute appendicitis. A 43-year-old premenopausal woman who was diagnosed with stage IIIA left breast cancer was scheduled for neoadjuvant chemotherapy includingfluorouracil plus epirubicin plus cyclophosphamide(FEC), followed by docetaxel and trastuzumab(DOC plus HER)...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29138379/-a-case-of-advanced-gastric-cancer-responding-to-neoadjuvant-chemotherapy-with-docetaxel-cisplatin-and-5-fluorouracil-leading-to-a-pathological-complete-response
#15
Keishi Kawasaki, Dan Takeuchi, Takaaki Kaneko, Seiki Miura, Junichiro Kamiya, Yoji Miyahara, Kotaro Yoshimura, Akira Ogata
We report a 72-year-old woman who was initially diagnosed with locally advanced gastric cancer with involvement of the esophagus and pancreas. She received 3 courses of neoadjuvant chemotherapy(NAC)with docetaxel, cisplatin, and 5- fluorouracil(the DCF regimen)and achieved an excellent response. She underwent total gastrectomy with distal pancreatectomy, splenectomy, and D2 lymphadenectomy. Histological examination confirmed a pathological complete response. NAC chemotherapy can down stage/down size the disease and allow some patients to undergo curative radical surgery...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29138067/the-prognostic-effect-of-changes-in-tumor-stage%C3%A2-and-nodal-status-after-neoadjuvant-chemotherapy-in-each-primary-breast-cancer%C3%A2-subtype
#16
Naoki Hayashi, Yuko Takahashi, Naoko Matsuda, Hiroko Tsunoda, Atsushi Yoshida, Koyu Suzuki, Seigo Nakamura, Hideko Yamauchi
BACKGROUND: Although the prognostic value of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) depends on the intrinsic subtype of breast cancer, it is not clear whether chemosensitivity itself, shown by a decreasing tumor burden after NAC, contributes to improved prognosis in primary breast cancer patients, especially in patients with non-pCR. The aim of this study was to assess the prognostic effect of changes in tumor stage or nodal status after NAC in each primary breast cancer subtype...
October 3, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29137065/primary-leiomyosarcoma-of-the-bone-a-case-report-and-a-review-of-the-literature
#17
Federica Recine, Alberto Bongiovanni, Roberto Casadei, Federica Pieri, Nada Riva, Alessandro De Vita, Laura Mercatali, Chiara Liverani, Chiara Spadazzi, Giacomo Miserocchi, Valentina Fausti, Dino Amadori, Toni Ibrahim
RATIONALE: Leiomyosarcoma (LMS) is a malignant sarcoma that can occur in different anatomic sites, including the bone, showing similar histological characteristics but heterogeneous clinical behavior and prognosis. Primary bone LMS was first described in 1965. It is a very rare sarcoma, accounting for <0.7% of all primary malignant bone tumors. PATIENT CONCERNS: We report the case of a 52-year-old male with primary bone LMS who presented with a solitary osteolytic lesion with focal cortical destruction in the left clavicle, seen on an x-ray and subsequent computed tomography (CT) scan...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29136212/neoadjuvant-and-adjuvant-therapy-for-stage-iii-non-small-cell-lung-cancer
#18
Shun-Ichi Watanabe, Kazuo Nakagawa, Kenji Suzuki, Kazuya Takamochi, Hiroyuki Ito, Jiro Okami, Keiju Aokage, Hisashi Saji, Hiroshige Yoshioka, Yoshitaka Zenke, Tadashi Aoki, Yasuhiro Tsutani, Morihito Okada
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local and microscopic systemic disease, because the 5-year survival of patients with Stage III NSCLC who underwent surgical resection alone has been dismal. One way to improve surgical outcome is the administration of chemotherapy before or after the surgical procedure. During the last two decades, many clinical studies have focused on developing optimal adjuvant or neoadjuvant chemotherapy regimens that can be combined with surgical treatment and/or radiotherapy...
November 9, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29136005/a-17-molecule-set-as-a-predictor-of-complete-response-to-neoadjuvant-chemotherapy-with-docetaxel-cisplatin-and-5-fluorouracil-in-esophageal-cancer
#19
Hajime Fujishima, Shoichi Fumoto, Tomotaka Shibata, Kohei Nishiki, Yoshiyuki Tsukamoto, Tsuyoshi Etoh, Masatsugu Moriyama, Norio Shiraishi, Masafumi Inomata
BACKGROUND: Recently, neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (NAC-DCF) was identified as a novel strong regimen with a high rate of pathological complete response (pCR) in advanced esophageal cancer in Japan. Predicting pCR will contribute to the therapeutic strategy and the prevention of surgical invasion. However, a predictor of pCR after NAC-DCF has not yet been developed. The aim of this study was to identify a novel predictor of pCR in locally advanced esophageal cancer treated with NAC-DCF...
2017: PloS One
https://www.readbyqxmd.com/read/29135102/changes-in-18f-fdg-pet-ct-tumor-metabolism-are-not-consistent-with-pathologic-complete-response-in-hormone-positive-breast-cancer
#20
Serap Kaya, Bilge Aktas, Eda Tanrikulu Sismek, Mehmet Akif Ozturk, Fuat Dede, Handan Kaya, Umit Ugurlu, Zerrin Ozgen, Sinan Koca, Suleyman Halil, Rahib Hasanov, Ozkan Alan, Nalan Akgul Babacan, Ozlem Ercelep, Faysal Dane, Mahmut Gumus, Fulden Yumuk
PURPOSE: Current evaluation of response to neoadjuvant chemotherapy (NAC) shows that it could achieve pathological complete response (pCR). The purpose of this study was to assess the consistency of maximum uptake values (SUVmax) changes and pCR in hormone-positive locally advanced breast cancer (LABC). METHODS: Ninety hormone-positive LABC patients treated at Marmara University Medical Oncology Clinic, Istanbul, Turkey, between 2009 and 2015 were retrospectively studied...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
keyword
keyword
9783
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"